Literature DB >> 16019725

The endocannabinoid system and the treatment of obesity.

Uberto Pagotto1, Valentina Vicennati, Renato Pasquali.   

Abstract

The endocannabinoids are endogenous lipids capable of binding to both cannabinoid receptors (CB) CB1 and CB2. These receptors belong to the G protein-coupled family receptors and they were discovered while investigating the mode of action of ?(9)-tetrahydrocannabinol, a component of Cannabis sativa, to which they bind with high affinity. Among many other brain sites, CB1 is present in the hypothalamic nuclei involved in the control of energy balance and body weight, as well as in neurons of the mesolimbic system which is believed to mediate the incentive value of food. At central nervous system level, CB1 activation is necessary to induce food intake after a short period of food deprivation, and when CB1 is activated by endocannabinoids produced in situ, a stimulation of the ingestion of palatable food has been described. CB1 stimulation leads to modulation of the release of some hypothalamic anorexigenic and orexigenic mediators, as well as of dopamine in the nucleus accumbens shell. Recent evidence has proved that CB1 is also present in the peripheral organs, such as the adipose tissue and gastrointestinal system, key organs in the regulation of energy metabolism. Animal models have provided solid evidence that genetically induced obesity leads to long-lasting overstimulation of endocannabinoid system synthesis resulting in permanent overactivation of CB1, which may then contribute to the maintenance of this disease. Importantly, at peripheral level, CB1 activation has been shown to stimulate lipogenesis in adipocytes. CB1 blockers increase adiponectin production in adipocytes, which leads to increased fatty acid oxidation and free fatty acid clearance. Moreover, CB1 has been shown to be up-regulated in adipocytes derived from obese rodents. These results support the role of endocannabinoids in the development and maintenance of obesity, paving the way for the development of a new class of drugs such as the CB1 blockers as a therapy for tackling obesity and the associated major cardiovascular risk factors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16019725     DOI: 10.1080/07853890510037419

Source DB:  PubMed          Journal:  Ann Med        ISSN: 0785-3890            Impact factor:   4.709


  18 in total

Review 1.  ABC of obesity. Management: part II--drugs.

Authors:  Mike Lean; Nick Finer
Journal:  BMJ       Date:  2006-10-14

Review 2.  Changes of Olfactory Performance during the Process of Aging - Psychophysical Testing and Its Relevance in the Fight against Malnutrition.

Authors:  W Gunzer
Journal:  J Nutr Health Aging       Date:  2017       Impact factor: 4.075

3.  Treatment options for obesity and potential therapies on the horizon.

Authors:  Carol A Motycka; Erin St Onge; Shannon A Miller
Journal:  P T       Date:  2011-05

4.  Comparative genetics of the central nervous system in epigean and hypogean Astyanax mexicanus.

Authors:  Allen G Strickler; Daphne Soares
Journal:  Genetica       Date:  2011-02-13       Impact factor: 1.082

5.  Cannabinoids excite hypothalamic melanin-concentrating hormone but inhibit hypocretin/orexin neurons: implications for cannabinoid actions on food intake and cognitive arousal.

Authors:  Hao Huang; Claudio Acuna-Goycolea; Ying Li; H M Cheng; Karl Obrietan; Anthony N van den Pol
Journal:  J Neurosci       Date:  2007-05-02       Impact factor: 6.167

Review 6.  Cannabinoids in eating disorders and obesity.

Authors:  Francisco Arias Horcajadas
Journal:  Mol Neurobiol       Date:  2007-07-07       Impact factor: 5.590

7.  Dissociable effects of CB1 receptor blockade on anxiety-like and consummatory behaviors in the novelty-induced hypophagia test in mice.

Authors:  Joyonna C Gamble-George; Jordan R Conger; Nolan D Hartley; Prerna Gupta; Joshua J Sumislawski; Sachin Patel
Journal:  Psychopharmacology (Berl)       Date:  2013-03-13       Impact factor: 4.530

8.  Marijuana's Influence on Pain Scores, Initial Weight Loss, and Other Bariatric Surgical Outcomes.

Authors:  Frank L Bauer; William T Donahoo; Harris W Hollis; Adam G Tsai; Brian J Pottorf; Jason M Johnson; Lori J Silveira; Farah A Husain
Journal:  Perm J       Date:  2018

9.  Rimonabant: the evidence for its use in the treatment of obesity and the metabolic syndrome.

Authors:  Mark Waterlow; Paul Chrisp
Journal:  Core Evid       Date:  2008-02-29

10.  Cannabinoid type 1 receptor mediates depot-specific effects on differentiation, inflammation and oxidative metabolism in inguinal and epididymal white adipocytes.

Authors:  I V Wagner; N Perwitz; M Drenckhan; H Lehnert; J Klein
Journal:  Nutr Diabetes       Date:  2011-09-05       Impact factor: 5.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.